Overview
Chronic intractable migraine without aura is a debilitating neurological condition characterized by frequent migraine attacks that significantly impair daily functioning and quality of life 13.Diagnosis
Diagnosis based on International Classification of Headache Disorders criteria 3.
No specific laboratory tests; clinical history and physical examination are crucial 3.
Exclusion of secondary causes through appropriate imaging if indicated 3.Management
First-line treatments:
- Preventive medications: Topiramate, CGRP monoclonal antibodies (e.g., Eptinezumab, Fremanezumab, Galcanezumab) 24.
- OnabotulinumtoxinA (Botox) injections every 12 weeks for preventive effect 35.
Adjunctive treatments:
- Physical therapy approaches including aerobic exercise, osteopathic manipulative treatment, and other modalities show promise in reducing headache frequency and improving quality of life 1.
- Consider non-pharmacological interventions like biofeedback and relaxation techniques 1.Special Populations
Pregnancy: Limited evidence; cautious use of preventive medications with close monitoring 4.
Elderly: Consider comorbidities and potential drug interactions when selecting preventive treatments 4.
Comorbidities: Tailor treatment plans considering coexisting conditions like medication overuse headache 4.Key Recommendations
Use onabotulinumtoxinA (Botox) as a first-line preventive treatment for chronic migraine, with significant evidence supporting its efficacy 35 (Evidence: Strong).
Consider CGRP monoclonal antibodies (e.g., Eptinezumab, Fremanezumab) for their robust effectiveness in reducing monthly headache days 24 (Evidence: Strong).
Incorporate physical therapy interventions such as aerobic exercise and manual therapies to complement pharmacological treatments, enhancing quality of life and reducing disability 1 (Evidence: Moderate).
Monitor and adjust treatment plans in elderly patients due to increased risk of comorbidities and drug interactions 4 (Evidence: Moderate).
Exercise caution with medication use during pregnancy, focusing on non-pharmacological strategies when possible 4 (Evidence: Weak).References
1 Onan D, Ekizoğlu E, Arıkan H, Taşdelen B, Özge A, Martelletti P. The Efficacy of Physical Therapy and Rehabilitation Approaches in Chronic Migraine: A Systematic Review and Meta-Analysis. Journal of integrative neuroscience 2023. link
2 Naghdi S, Underwood M, Madan J, Brown A, Duncan C, Matharu M et al.. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. The journal of headache and pain 2023. link
3 Turkel CC, Aurora S, Diener HC, Dodick DW, Lipton RB, Silberstein SD et al.. Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine 2023. link
4 Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia : an international journal of headache 2023. link
5 Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia : an international journal of headache 2022. link
6 Goadsby PJ, Goasdby PJ. Hemicrania continua--building on experience and clinical science. The journal of headache and pain 2014. link